Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
BOTHELL, Wash., March 27, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) today announced that it will host a conference call and simultaneous webcast Monday, March 28, 2016, at 8:30 a.m. ET, to review top-line data from its Phase 2b clinical trial evaluating ALD403 in patients with chronic migraine and top-line data from its Phase 1 clinical trial evaluating multiple doses of ALD403 through various modes of administration in healthy volunteers.
Conference Call Details
The live call may be accessed by dialing 877-430-4657 for domestic callers or 484-756-4339 for international callers, and providing conference ID number 80096426.
The webcast, with slides, will be broadcast live on the Events & Presentations page of the Investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.
Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 [email protected]
